ClinicalTrials.gg

Program

BMN 333

A development code.

Its studies are mostly in Achondroplasia, led by BioMarin Pharmaceutical.

Furthest: phase 3, since Feb 11, 20261 company-led study, 1 open or runningNext primary completion: Jun 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioMarin Pharmaceutical11 open or runningphase 3since Feb 11, 2026Feb 11, 2026Jun 2029phase 3 · NCT07441876

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 11, 2026First study: phase 3 study in AchondroplasiaFirst studyNCT07441876 · 160 planned · United States, Australia, Canada and more

Ahead

  1. Jun 2029Primary completion: phase 3 study in AchondroplasiaNCT07441876

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07441876Achondroplasia · United States, Australia, Canada and more3RecruitingJun 2029160

How it is read

Names in the registry

  • “BMN 333”, 1 entry

Codes read as this program: BMN333.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.